0.6215

5.63% -0.0371

After Hours: .65 0.0285 +4.59%

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $0.6215, with a volume of 1.66M. It is down -5.63% in the last 24 hours and down -20.06% over the past month. Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Previous Close:

$0.6586

Open:

$0.651

24h Volume:

1.66M

Relative Volume:

1.61

Market Cap:

$80.28M

Revenue:

Net Income/Loss:

$-26.91M

P/E Ratio:

-2.825

EPS:

-0.22

Net Cash Flow:

$-19.57M

1W Performance:

-9.15%

1M Performance:

-20.06%

6M Performance:

-29.33%

1Y Performance:

-36.20%

1-Day Range:

$0.6151

$0.6548

1-Week Range:

$0.6151

$0.6967

52-Week Range:

$0.5526

$1.29

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

206.588.0256

Address

10202 5TH AVENUE NE, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2025-03-25

Latest SEC Filings

ATOS's Discussions on Twitter

Compare ATOS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATOS Atossa Therapeutics Inc	0.6215	85.07M	0	-26.91M	-19.57M	-0.22
VRTX Vertex Pharmaceuticals Inc	453.74	116.65B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	773.94	82.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	397.25	52.69B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	837.90	51.56B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.09	37.61B	447.02M	-1.18B	-906.14M	-6.1812

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

Dec 29, 2025

Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals

Dec 29, 2025

Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World

Dec 29, 2025

Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Dec 29, 2025

Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Dec 29, 2025

Dec 27, 2025

Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World

Dec 27, 2025

Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat

Dec 27, 2025

Dec 25, 2025

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Norwich Bulletin

Dec 25, 2025

Dec 22, 2025

Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World

Dec 22, 2025

Dec 21, 2025

What margin trends mean for Atossa Therapeutics Inc. stockWeekly Trade Summary & Growth Focused Stock Reports - Улправда

Dec 21, 2025

Dec 20, 2025

Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда

Dec 20, 2025

Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда

Dec 20, 2025

Atossa Therapeutics Earnings Notes - Trefis

Dec 20, 2025

Dec 19, 2025

Will Atossa Therapeutics Inc. stock benefit from AI adoptionWeekly Profit Recap & Consistent Return Strategy Ideas - DonanımHaber

Dec 19, 2025

Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber

Dec 19, 2025

Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда

Dec 19, 2025

Dec 18, 2025

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace

Dec 18, 2025

Dec 17, 2025

Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena

Dec 17, 2025

Dec 16, 2025

Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Dec 16, 2025

Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Dec 16, 2025

Dec 15, 2025

Atossa Therapeutics (ATOS) Highlights Promising (Z)-endoxifen Tr - GuruFocus

Dec 15, 2025

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium - WV News

Dec 15, 2025

Dec 14, 2025

Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits

Dec 14, 2025

Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn

Dec 14, 2025

Dec 13, 2025

Atossa gains on rare pediatric disease status for Duchenne asset - MSN

Dec 13, 2025

Dec 12, 2025